Table 4.
Open in new tab

Cox regression analyses for the determinants of no remission after recurrence of MPGN (41 events)

Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).44
 <301.00 (reference)
 30–601.28 (0.34–4.87)
 >602.16 (0.52–8.90)
Gender.18
 Female1.00 (reference)
 Male1.91 (0.74–4.94)
Transplantation decade.21
 1981–19901.00 (reference)
 1991–20001.53 (0.11–2.16)
 2001–20100.66 (0.04–9.93)
 2011–20212.45 (0.14–4.81)
Time to recurrence (months)<.001<.001
 >151.00 (reference)1.00 (reference)
 ≤155.64 (2.22–14.3)4.23 (2.09–9.41)
eGFR at recurrence (mL/min/1.73 m2).04.02
 ≥301.00 (reference)1.00 (reference)
 <302.31 (1.02–5.25)2.11 (1.12–4.15)
Serum albumin at recurrence (g/dL)<.001.005
 ≥3.51.00 (reference)1.00 (reference)
 <3.54.88 (2.19–10.85)2.56 (1.34–4.91)
Serum C3 at recurrence (mg/dL).28
 ≥801.00 (reference)
 <802.16 (0.52–8.90)
Proteinuria at recurrence (g/24 h).31
 ≥3.51.00 (reference)
 <3.50.67 (0.30–1.47)
Globally sclerotic glomeruli, n %.040.06
 ≤501.00 (reference)1.00 (reference)
 >501.04 (1.01–1.08)1.05 (0.98–1.09)
Tubular atrophy/interstitial fibrosis, n (%).72
 ≤201.00 (reference)
 20–500.65 (0.22–1.95)
 >500.42 (0.09–2.02)
Mesangial proliferation, n (%).24
 ≤201.00 (reference)
 20–500.44 (0.17–1.16)
 >500.65 (0.27–1.57)
Endocapillary proliferation, n (%).39
 ≤201.00 (reference)
 20–501.73 (0.76–3.96)
 >501.27 (0.51–3.17)
Leukocyte infiltration, n (%).43
 ≤201.00 (reference)
 20–500.62 (0.29–1.28)
 >500.90 (0.27–3.01)
Cellular or fibrocellular crescents, n (%).19
 No1.00 (reference)
 Yes0.25 (0.03–1.97)
Double contour of GBM, n (%).09
 ≤201.00 (reference)
 20–500.68 (0.32–1.46)
 >501.82 (0.74–4.49)
Interstitial inflammation, n (%).53
 ≤201.00 (reference)
 20–500.80 (0.38–1.67)
 >502.54 (0.34–3.63)
Rejection episode during follow-up.07
 No1.00 (reference)
 Yes1.92 (0.89–4.06)
Treatment with corticosteroids for recurrence.14
 No1.00 (reference)
 Yes0.44 (0.15–1.29)
Treatment with rituximab for recurrence.16
 No1.00 (reference)
 Yes0.47 (0.17–1.34)
Treatment with plasma exchange for recurrence.16
 No1.00 (reference)
 Yes2.18 (0.73–6.52)
Treatment with MMF dose increase for recurrence.62
 No1.00 (reference)
 Yes0.72 (0.20–2.65)
Treatment with eculizumab for recurrence.47
 No1.00 (reference)
 Yes0.61 (0.16–2.36)
Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).44
 <301.00 (reference)
 30–601.28 (0.34–4.87)
 >602.16 (0.52–8.90)
Gender.18
 Female1.00 (reference)
 Male1.91 (0.74–4.94)
Transplantation decade.21
 1981–19901.00 (reference)
 1991–20001.53 (0.11–2.16)
 2001–20100.66 (0.04–9.93)
 2011–20212.45 (0.14–4.81)
Time to recurrence (months)<.001<.001
 >151.00 (reference)1.00 (reference)
 ≤155.64 (2.22–14.3)4.23 (2.09–9.41)
eGFR at recurrence (mL/min/1.73 m2).04.02
 ≥301.00 (reference)1.00 (reference)
 <302.31 (1.02–5.25)2.11 (1.12–4.15)
Serum albumin at recurrence (g/dL)<.001.005
 ≥3.51.00 (reference)1.00 (reference)
 <3.54.88 (2.19–10.85)2.56 (1.34–4.91)
Serum C3 at recurrence (mg/dL).28
 ≥801.00 (reference)
 <802.16 (0.52–8.90)
Proteinuria at recurrence (g/24 h).31
 ≥3.51.00 (reference)
 <3.50.67 (0.30–1.47)
Globally sclerotic glomeruli, n %.040.06
 ≤501.00 (reference)1.00 (reference)
 >501.04 (1.01–1.08)1.05 (0.98–1.09)
Tubular atrophy/interstitial fibrosis, n (%).72
 ≤201.00 (reference)
 20–500.65 (0.22–1.95)
 >500.42 (0.09–2.02)
Mesangial proliferation, n (%).24
 ≤201.00 (reference)
 20–500.44 (0.17–1.16)
 >500.65 (0.27–1.57)
Endocapillary proliferation, n (%).39
 ≤201.00 (reference)
 20–501.73 (0.76–3.96)
 >501.27 (0.51–3.17)
Leukocyte infiltration, n (%).43
 ≤201.00 (reference)
 20–500.62 (0.29–1.28)
 >500.90 (0.27–3.01)
Cellular or fibrocellular crescents, n (%).19
 No1.00 (reference)
 Yes0.25 (0.03–1.97)
Double contour of GBM, n (%).09
 ≤201.00 (reference)
 20–500.68 (0.32–1.46)
 >501.82 (0.74–4.49)
Interstitial inflammation, n (%).53
 ≤201.00 (reference)
 20–500.80 (0.38–1.67)
 >502.54 (0.34–3.63)
Rejection episode during follow-up.07
 No1.00 (reference)
 Yes1.92 (0.89–4.06)
Treatment with corticosteroids for recurrence.14
 No1.00 (reference)
 Yes0.44 (0.15–1.29)
Treatment with rituximab for recurrence.16
 No1.00 (reference)
 Yes0.47 (0.17–1.34)
Treatment with plasma exchange for recurrence.16
 No1.00 (reference)
 Yes2.18 (0.73–6.52)
Treatment with MMF dose increase for recurrence.62
 No1.00 (reference)
 Yes0.72 (0.20–2.65)
Treatment with eculizumab for recurrence.47
 No1.00 (reference)
 Yes0.61 (0.16–2.36)

Significant values in bold.

GBM, glomerular basement membrane; MMF, mycophenolate mofetil.

Table 4.
Open in new tab

Cox regression analyses for the determinants of no remission after recurrence of MPGN (41 events)

Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).44
 <301.00 (reference)
 30–601.28 (0.34–4.87)
 >602.16 (0.52–8.90)
Gender.18
 Female1.00 (reference)
 Male1.91 (0.74–4.94)
Transplantation decade.21
 1981–19901.00 (reference)
 1991–20001.53 (0.11–2.16)
 2001–20100.66 (0.04–9.93)
 2011–20212.45 (0.14–4.81)
Time to recurrence (months)<.001<.001
 >151.00 (reference)1.00 (reference)
 ≤155.64 (2.22–14.3)4.23 (2.09–9.41)
eGFR at recurrence (mL/min/1.73 m2).04.02
 ≥301.00 (reference)1.00 (reference)
 <302.31 (1.02–5.25)2.11 (1.12–4.15)
Serum albumin at recurrence (g/dL)<.001.005
 ≥3.51.00 (reference)1.00 (reference)
 <3.54.88 (2.19–10.85)2.56 (1.34–4.91)
Serum C3 at recurrence (mg/dL).28
 ≥801.00 (reference)
 <802.16 (0.52–8.90)
Proteinuria at recurrence (g/24 h).31
 ≥3.51.00 (reference)
 <3.50.67 (0.30–1.47)
Globally sclerotic glomeruli, n %.040.06
 ≤501.00 (reference)1.00 (reference)
 >501.04 (1.01–1.08)1.05 (0.98–1.09)
Tubular atrophy/interstitial fibrosis, n (%).72
 ≤201.00 (reference)
 20–500.65 (0.22–1.95)
 >500.42 (0.09–2.02)
Mesangial proliferation, n (%).24
 ≤201.00 (reference)
 20–500.44 (0.17–1.16)
 >500.65 (0.27–1.57)
Endocapillary proliferation, n (%).39
 ≤201.00 (reference)
 20–501.73 (0.76–3.96)
 >501.27 (0.51–3.17)
Leukocyte infiltration, n (%).43
 ≤201.00 (reference)
 20–500.62 (0.29–1.28)
 >500.90 (0.27–3.01)
Cellular or fibrocellular crescents, n (%).19
 No1.00 (reference)
 Yes0.25 (0.03–1.97)
Double contour of GBM, n (%).09
 ≤201.00 (reference)
 20–500.68 (0.32–1.46)
 >501.82 (0.74–4.49)
Interstitial inflammation, n (%).53
 ≤201.00 (reference)
 20–500.80 (0.38–1.67)
 >502.54 (0.34–3.63)
Rejection episode during follow-up.07
 No1.00 (reference)
 Yes1.92 (0.89–4.06)
Treatment with corticosteroids for recurrence.14
 No1.00 (reference)
 Yes0.44 (0.15–1.29)
Treatment with rituximab for recurrence.16
 No1.00 (reference)
 Yes0.47 (0.17–1.34)
Treatment with plasma exchange for recurrence.16
 No1.00 (reference)
 Yes2.18 (0.73–6.52)
Treatment with MMF dose increase for recurrence.62
 No1.00 (reference)
 Yes0.72 (0.20–2.65)
Treatment with eculizumab for recurrence.47
 No1.00 (reference)
 Yes0.61 (0.16–2.36)
Univariate analysisMultivariate analysis
VariableHR (95% CI)P-valueAdjusted HR (95% CI)P-value
Age at transplantation (years).44
 <301.00 (reference)
 30–601.28 (0.34–4.87)
 >602.16 (0.52–8.90)
Gender.18
 Female1.00 (reference)
 Male1.91 (0.74–4.94)
Transplantation decade.21
 1981–19901.00 (reference)
 1991–20001.53 (0.11–2.16)
 2001–20100.66 (0.04–9.93)
 2011–20212.45 (0.14–4.81)
Time to recurrence (months)<.001<.001
 >151.00 (reference)1.00 (reference)
 ≤155.64 (2.22–14.3)4.23 (2.09–9.41)
eGFR at recurrence (mL/min/1.73 m2).04.02
 ≥301.00 (reference)1.00 (reference)
 <302.31 (1.02–5.25)2.11 (1.12–4.15)
Serum albumin at recurrence (g/dL)<.001.005
 ≥3.51.00 (reference)1.00 (reference)
 <3.54.88 (2.19–10.85)2.56 (1.34–4.91)
Serum C3 at recurrence (mg/dL).28
 ≥801.00 (reference)
 <802.16 (0.52–8.90)
Proteinuria at recurrence (g/24 h).31
 ≥3.51.00 (reference)
 <3.50.67 (0.30–1.47)
Globally sclerotic glomeruli, n %.040.06
 ≤501.00 (reference)1.00 (reference)
 >501.04 (1.01–1.08)1.05 (0.98–1.09)
Tubular atrophy/interstitial fibrosis, n (%).72
 ≤201.00 (reference)
 20–500.65 (0.22–1.95)
 >500.42 (0.09–2.02)
Mesangial proliferation, n (%).24
 ≤201.00 (reference)
 20–500.44 (0.17–1.16)
 >500.65 (0.27–1.57)
Endocapillary proliferation, n (%).39
 ≤201.00 (reference)
 20–501.73 (0.76–3.96)
 >501.27 (0.51–3.17)
Leukocyte infiltration, n (%).43
 ≤201.00 (reference)
 20–500.62 (0.29–1.28)
 >500.90 (0.27–3.01)
Cellular or fibrocellular crescents, n (%).19
 No1.00 (reference)
 Yes0.25 (0.03–1.97)
Double contour of GBM, n (%).09
 ≤201.00 (reference)
 20–500.68 (0.32–1.46)
 >501.82 (0.74–4.49)
Interstitial inflammation, n (%).53
 ≤201.00 (reference)
 20–500.80 (0.38–1.67)
 >502.54 (0.34–3.63)
Rejection episode during follow-up.07
 No1.00 (reference)
 Yes1.92 (0.89–4.06)
Treatment with corticosteroids for recurrence.14
 No1.00 (reference)
 Yes0.44 (0.15–1.29)
Treatment with rituximab for recurrence.16
 No1.00 (reference)
 Yes0.47 (0.17–1.34)
Treatment with plasma exchange for recurrence.16
 No1.00 (reference)
 Yes2.18 (0.73–6.52)
Treatment with MMF dose increase for recurrence.62
 No1.00 (reference)
 Yes0.72 (0.20–2.65)
Treatment with eculizumab for recurrence.47
 No1.00 (reference)
 Yes0.61 (0.16–2.36)

Significant values in bold.

GBM, glomerular basement membrane; MMF, mycophenolate mofetil.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close